Bolt Biotherapeutics’ share price rose about 59% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
A share-price change alone does not show whether a business improved or worsened. The article gives no reason tied to BOLT’s products, trials, sales, or finances, so it does not change how we read the company’s outlook.
Lucid Diagnostics’ share price rose about 34% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
Estrella Immunopharma’s share price rose about 27% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
Nautilus Biotechnology’s share price rose about 21% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
NeOnc Technologies Hldgs’ share price rose about 18% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
Aardvark Therapeutics’ share price fell about 57% during Friday’s session, but the article gives no business reason for the drop. It adds no new information about the company’s outlook.
Follow Bolt Biotherapeutics (BOLT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BOLT